

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA RENJI MEDICAL GROUP LIMITED

中國仁濟醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

PROFIT WARNING

This announcement is made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance.

Based on the preliminary estimation of the Company, the Board wishes to inform the shareholders of the Company and potential investors that the Group may potentially incur a significant impairment loss on its assets and may therefore result in recording of a loss in its consolidated financial statements for the six months ending 30 June 2013 as compared to a net profit recorded during the corresponding period in 2012.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by China Renji Medical Group Limited (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “Listing Rules”) on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on the preliminary estimation of the Company and the information currently available, the board (the “Board”) of directors (the “Directors”) of the Company wishes to inform the shareholders of the Company and potential investors that due to the recent implementation of the new policies of China’s medical industry which have imposed adverse impact on the Group’s medical business, the Group may potentially incur a significant impairment loss on its assets (including plant and equipment and other intangible assets) and may therefore result in recording of a loss in its consolidated financial statements for the six months ending 30 June 2013 as compared to a net profit recorded during the corresponding period in 2012.

The information contained in this announcement is only a preliminary assessment by the Group's management based on the currently available unaudited financial information of the Group, which has not been audited or reviewed by the auditors of the Company. Shareholders of the Company and potential investors are advised to read carefully the consolidated interim results announcement of the Group for the six months ending 30 June 2013 once it is finalised and published in accordance with the requirement of the Listing Rules.

Shareholders of the Company and potential investors are advised to exercise caution in dealing in the shares of the Company.

By Order of the Board of
China Renji Medical Group Limited
Tang Chi Chiu
Chairman

Hong Kong, 18 June 2013

As at the date of this announcement, the Board comprises two executive Directors, namely Mr. Tang Chi Chiu and Mr. Wang Jianguo; and three independent non-executive Directors, namely, Mr. Kwok Chung On, Mr. Wu Chi Keung and Ms. Wu Yan.